WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong
· Delayed Price · Currency is HKD 32.62
-0.32 (-0.97%)
At close: Dec 5, 2025
WuXi Biologics Revenue
WuXi Biologics had revenue of 9.95B CNY in the half year ending June 30, 2025, with 17.21% growth. This brings the company's revenue in the last twelve months to 20.05B, up 17.16% year-over-year. In the year 2024, WuXi Biologics had annual revenue of 18.68B with 9.63% growth.
Revenue (ttm)
20.05B CNY
Revenue Growth
+17.16%
P/S Ratio
6.11
Revenue / Employee
1.59M CNY
Employees
12,575
Market Cap
134.32B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18.68B | 1.64B | 9.63% |
| Dec 31, 2023 | 17.03B | 1.77B | 11.56% |
| Dec 31, 2022 | 15.27B | 4.98B | 48.38% |
| Dec 31, 2021 | 10.29B | 4.68B | 83.35% |
| Dec 31, 2020 | 5.61B | 1.63B | 40.88% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |
| Alibaba Health Information Technology | 36.09B |
WuXi Biologics News
- 3 days ago - WuXi Biologics Extends Global CRDMO Network to Qatar Through Strategic MoU Signed with Qatar Free Zones Authority - PRNewsWire
- 4 days ago - WuXi Biologics Signs MoU With Qatar Free Zones Authority To Set Up Middle East CRDMO Center - Nasdaq
- 6 weeks ago - WuXi Biologics Included in Hang Seng Corporate Sustainability Benchmark Index - PRNewsWire
- 6 weeks ago - WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition by Frost & Sullivan - PRNewsWire
- 2 months ago - WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year - PRNewsWire
- 2 months ago - WuXi Biologics Launches WuXia™4.0, Targeted Integration Cell Line Platform TrueSite TI™，to Accelerate Biologics Development with High Titer and Superior Stability - PRNewsWire
- 2 months ago - WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year - PRNewsWire
- 2 months ago - Chinese biotechs get a shot in the arm from policy support, licensing deals - South China Morning Post